HIV & Hepatitis Management

15th Annual CME Symposium Overview

In the 35+ years since recognition of the AIDS epidemic, HIV disease has evolved into a manageable chronic disease for patients with access to state-of-the-art care. In the 25+ years since identifying hepatitis C as a distinct entity, we can cure the infection in the vast majority of patients that we are able to treat. While we are unable as yet to cure HIV infection or many patients with chronic hepatitis B, research into possible cures continues.

This advanced CME set of activities will provide participants with state-of-the-art information and practical guidance from internationally recognized experts on progress in managing HIV, hepatitis B, and hepatitis C, including drug development and treatment, management of important comorbidities and drug-drug interactions, enabling practitioners to deliver the highest quality care in all practice settings.

The primary goals of this activity are to increase each participant's competence to:

  • Illustrate advances in approaches to prevent and treat HIV infection, hepatitis B and hepatitis C
  • Apply new information to manage disease in difficult-to-treat situations
  • Manage patients with immune activation or immunosuppression
  • Understand, avoid and manage drug-drug interactions complicating treatment
  • Manage common and important comorbidities in patients with HIV infection, including cardiovascular, neoplastic, neurocognitive and sexually transmitted disorders and diabetes mellitus
  • Identify important management considerations in patients coinfected with multiple viral infections
  • Recognize that due to ongoing risk of liver disease, long-term care of patients with chronic viral hepatitis is often necessary, even after cure of the infection

Click any title below to start that activity.

HIV Activities
Each activity worth 0.75 credits
Immune-Based Therapies
Peter W. Hunt, MD
Antiretroviral Therapy Progress
Roy M. Gulick, MD, MPH
ART: What to Start and When to Switch
Joel E. Gallant, MD, MPH
Biomedical Prevention Update
Thomas C. Quinn, MD, MSc
Diabetes Risk Assessment and Treatment
Todd T. Brown, MD, PhD
Update on Sexually Transmitted Infections
Jeanne M. Marrazzo, MD, MPH
Beyond MI: Cardiovascular Disease in the ART-Treated Patient
Christopher T. Longenecker, MD
AIDS-Related Cancers: What's New with the Old
Alexandra M. Levine, MD, MACP
HIV and Aging: Optimizing Neurocognitive Function
Scott L. Letendre, MD
What Every HIV Clinician Needs to Know About Infectious Diseases
John G. Bartlett, MD
Hepatitis Activities
Each activity worth 0.75 credits
The Cost of NOT Treating HCV Infection
David L. Thomas, MD, MPH
The ABCs of Liver Disease
John F. Reinus, MD
Managing After the Cure: Hepatocellular Carcinoma, Fatty Liver Disease and More
Robert S. Brown, Jr., MD, MPH
HBV Treatment Pipeline: Prospects for a Cure
Marion Peters, MD
HBV Diagnosis and Treatment: State of the Art
Anna S. Lok, MD
HBV Reactivation: A Preventable Menace
Raymond T. Chung, MD
Controversies in Hepatitis C Management
Michael R. Charlton, MD
Drug-Drug Interactions of HBV and HCV Regimens
David J. Back, PhD
Hepatitis C Therapies: State of the Art
Elizabeth C. Verna, MD, MS
Retreatment in the Face of DAA Resistance
David L. Wyles, MD